WO2014041115A3 - Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung - Google Patents

Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung Download PDF

Info

Publication number
WO2014041115A3
WO2014041115A3 PCT/EP2013/068992 EP2013068992W WO2014041115A3 WO 2014041115 A3 WO2014041115 A3 WO 2014041115A3 EP 2013068992 W EP2013068992 W EP 2013068992W WO 2014041115 A3 WO2014041115 A3 WO 2014041115A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel
peptides derived
enantiomeric peptides
enantiomeric
homologs
Prior art date
Application number
PCT/EP2013/068992
Other languages
English (en)
French (fr)
Other versions
WO2014041115A2 (de
Inventor
Dieter Willbold
Oleksander Brener
Susanne Aileen Funke
Luitgard Nagel-Steger
Dirk Bartnik
Antonia Nicole KLEIN
Original Assignee
Forschungszentrum Jülich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Jülich GmbH filed Critical Forschungszentrum Jülich GmbH
Priority to DK13776426.2T priority Critical patent/DK2895867T3/da
Priority to US14/426,797 priority patent/US20150307552A1/en
Priority to JP2015531567A priority patent/JP6345670B2/ja
Priority to EP13776426.2A priority patent/EP2895867B1/de
Priority to ES13776426T priority patent/ES2768264T3/es
Priority to EP17172220.0A priority patent/EP3346273B1/de
Priority to CN201380047981.9A priority patent/CN104704371B/zh
Publication of WO2014041115A2 publication Critical patent/WO2014041115A2/de
Publication of WO2014041115A3 publication Critical patent/WO2014041115A3/de
Priority to US15/482,968 priority patent/US10167318B2/en
Priority to US16/200,820 priority patent/US10889618B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Die vorliegende Erfindung betrifft neue, D-enantiomere A-Beta-Oligomerbindende Peptide, Homologe, Fragmente, Teile und Polymere davon sowie deren Verwendung.
PCT/EP2013/068992 2012-09-14 2013-09-13 Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung WO2014041115A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DK13776426.2T DK2895867T3 (da) 2012-09-14 2013-09-13 Hidtil ukendte d-enantiomer peptider afledt af d3 og anvendelse deraf
US14/426,797 US20150307552A1 (en) 2012-09-14 2013-09-13 Novel d-enantiomeric peptides derived from d3 and use thereof
JP2015531567A JP6345670B2 (ja) 2012-09-14 2013-09-13 Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用
EP13776426.2A EP2895867B1 (de) 2012-09-14 2013-09-13 Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung
ES13776426T ES2768264T3 (es) 2012-09-14 2013-09-13 Nuevos péptidos D-enantioméricos derivados de D3 y su uso
EP17172220.0A EP3346273B1 (de) 2012-09-14 2013-09-13 Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung
CN201380047981.9A CN104704371B (zh) 2012-09-14 2013-09-13 新的由d3衍生的d‑对映体肽及其用途
US15/482,968 US10167318B2 (en) 2012-09-14 2017-04-10 D-enantiomeric peptides derived from D3 and use thereof
US16/200,820 US10889618B2 (en) 2012-09-14 2018-11-27 D-enantiomeric peptides derived from D3 and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012108598.6 2012-09-14
DE102012108598.6A DE102012108598A1 (de) 2012-09-14 2012-09-14 Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/426,797 A-371-Of-International US20150307552A1 (en) 2012-09-14 2013-09-13 Novel d-enantiomeric peptides derived from d3 and use thereof
US15/482,968 Continuation US10167318B2 (en) 2012-09-14 2017-04-10 D-enantiomeric peptides derived from D3 and use thereof

Publications (2)

Publication Number Publication Date
WO2014041115A2 WO2014041115A2 (de) 2014-03-20
WO2014041115A3 true WO2014041115A3 (de) 2014-06-26

Family

ID=49354628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/068992 WO2014041115A2 (de) 2012-09-14 2013-09-13 Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung

Country Status (9)

Country Link
US (3) US20150307552A1 (de)
EP (2) EP3346273B1 (de)
JP (2) JP6345670B2 (de)
CN (2) CN104704371B (de)
DE (1) DE102012108598A1 (de)
DK (2) DK2895867T3 (de)
ES (2) ES2768264T3 (de)
PL (1) PL3346273T3 (de)
WO (1) WO2014041115A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
DE102015003503A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Spezifisch Amyloid-Beta bindende Peptide und deren Verwendung für die Therapie und Diagnose der Alzheimerschen Demenz
DE102015003676A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
DE102016125645A1 (de) * 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz
WO2019070645A1 (en) * 2017-10-02 2019-04-11 Cedars-Sinai Medical Center METHODS AND COMPOSITIONS FOR EFFECTIVE ADMINISTRATION THROUGH MULTIPLE BIOLOGICAL BARRIERS
DE102021121435A1 (de) * 2021-08-18 2023-02-23 Priavoid Gmbh Aß-BINDENDE SUBSTANZEN

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042462A2 (en) * 2000-11-27 2002-05-30 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2007047967A2 (en) * 2005-10-21 2007-04-26 Senicure, Llc Detoxification depot for alzheimer's disease
WO2010062570A2 (en) * 2008-10-27 2010-06-03 Recombinant Technologies Llc COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE
WO2011147797A2 (de) * 2010-05-28 2011-12-01 Forschungszentrum Jülich GmbH Hybrid-verbindung, deren verwendung und verfahren zu deren herstellung
WO2013150127A2 (de) * 2012-04-05 2013-10-10 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
WO2013150126A2 (de) * 2012-04-05 2013-10-10 Forschungzentrum Jülich Gmbh Verfahren zur behandlung von blut, blutprodukten und organen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002081515A1 (ja) * 2001-04-03 2004-07-29 協和醗酵工業株式会社 インスリン様増殖因子結合蛋白質
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042462A2 (en) * 2000-11-27 2002-05-30 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2007047967A2 (en) * 2005-10-21 2007-04-26 Senicure, Llc Detoxification depot for alzheimer's disease
WO2010062570A2 (en) * 2008-10-27 2010-06-03 Recombinant Technologies Llc COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE
WO2011147797A2 (de) * 2010-05-28 2011-12-01 Forschungszentrum Jülich GmbH Hybrid-verbindung, deren verwendung und verfahren zu deren herstellung
WO2013150127A2 (de) * 2012-04-05 2013-10-10 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
WO2013150126A2 (de) * 2012-04-05 2013-10-10 Forschungzentrum Jülich Gmbh Verfahren zur behandlung von blut, blutprodukten und organen

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANDREAS MÜLLER-SCHIFFMANN ET AL: "Combining Independent Drug Classes into Superior, Synergistically Acting Hybrid Molecules", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 49, no. 46, 8 November 2010 (2010-11-08), pages 8743 - 8746, XP055083717, ISSN: 1433-7851, DOI: 10.1002/anie.201004437 *
DIRK BARTNIK ET AL: "Differently selected D-enantiomeric peptides act on different A.beta. species", REJUVENATION RESEARCH, MARY ANN LIEBERT, NEW ROCHELLE, NY, US, vol. 13, no. 2-3, 12 May 2010 (2010-05-12), pages 202 - 205, XP002654152, ISSN: 1549-1684, [retrieved on 20091202], DOI: 10.1089/REJ.2009.0924 *
FUNKE SUSANNE AILEEN ET AL: "Peptides for Therapy and Diagnosis of Alzheimer's Disease", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, vol. 18, no. 6, 1 February 2012 (2012-02-01), pages 755 - 767, XP009170739, ISSN: 1381-6128 *
KATJA WIESEHAN ET AL: "Selection of D-Amino-Acid Peptides That Bind to Alzheimer's Disease Amyloid Peptide A[beta]142 by Mirror Image Phage Display", CHEMBIOCHEM, vol. 4, no. 8, 4 August 2003 (2003-08-04), pages 748 - 753, XP055069247, ISSN: 1439-4227, DOI: 10.1002/cbic.200300631 *
RANJINI K. SUNDARAM ET AL: "Novel Detox Gel Depot Sequesters [beta]-Amyloid Peptides in a Mouse Model of Alzheimer's Disease", INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, vol. 18, no. 2, 1 June 2012 (2012-06-01), pages 99 - 106, XP055070073, ISSN: 1573-3149, DOI: 10.1007/s10989-011-9283-7 *
SIDHARTHA M. CHAFEKAR ET AL: "Branched KLVFF Tetramers Strongly Potentiate Inhibition of [beta]-Amyloid Aggregation", CHEMBIOCHEM, vol. 8, no. 15, 15 October 2007 (2007-10-15), pages 1857 - 1864, XP055052606, ISSN: 1439-4227, DOI: 10.1002/cbic.200700338 *
STAINS CLIFF I ET AL: "Molecules that target beta-amyloid", CHEMMEDCHEM, WILEY - VCH VERLAG., WEINHEIM, DE, vol. 2, no. 12, 1 December 2007 (2007-12-01), pages 1675 - 1692, XP009107501, ISSN: 1860-7179, DOI: 10.1002/CMDC.200700140 *
SUSANNE AILEEN FUNKE ET AL: "Mirror image phage display-a method to generate d-peptide ligands for use in diagnostic or therapeutical applications", MOLECULAR BIOSYSTEMS, vol. 5, no. 8, 1 January 2009 (2009-01-01), pages 783, XP055069250, ISSN: 1742-206X, DOI: 10.1039/b904138a *
ZHANG GUOBAO ET AL: "Multiple-peptide conjugates for binding beta-amyloid plaques of Alzheimer's disease", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 14, no. 1, 1 January 2003 (2003-01-01), pages 86 - 92, XP002467772, ISSN: 1043-1802, DOI: 10.1021/BC025526I *

Also Published As

Publication number Publication date
CN107556375A (zh) 2018-01-09
EP3346273A1 (de) 2018-07-11
US20190085030A1 (en) 2019-03-21
EP3346273A8 (de) 2018-08-29
CN104704371B (zh) 2017-11-07
PL3346273T3 (pl) 2023-04-11
US20170313744A1 (en) 2017-11-02
JP2015531348A (ja) 2015-11-02
US20150307552A1 (en) 2015-10-29
EP2895867B1 (de) 2019-10-23
US10889618B2 (en) 2021-01-12
DK3346273T3 (da) 2023-02-27
WO2014041115A2 (de) 2014-03-20
DE102012108598A1 (de) 2014-04-10
US10167318B2 (en) 2019-01-01
ES2768264T3 (es) 2020-06-22
EP3346273B1 (de) 2023-01-04
JP6611858B2 (ja) 2019-11-27
ES2938773T3 (es) 2023-04-14
CN104704371A (zh) 2015-06-10
DK2895867T3 (da) 2020-02-03
EP2895867A2 (de) 2015-07-22
JP2018141008A (ja) 2018-09-13
JP6345670B2 (ja) 2018-06-20

Similar Documents

Publication Publication Date Title
IL238192B (en) Antibodies that recognize alpha-synuclei, preparations containing them and their uses
WO2014071419A3 (en) Novel fusion molecules and uses thereof
EP3186277A4 (de) Antikörper, zusammensetzungen und verwendung
WO2013165894A3 (en) St2l antagonists and methods of use
EP3141570A4 (de) Durch polykondensation hergestelltes harz und harzzusammensetzung
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
EP3129040A4 (de) Mimetische hepdicinpeptide und verwendungen davon
ZA201405310B (en) Compressor device, as well as the use of such an assembly
CN104540941A8 (zh) 获得肽的方法
EP3166959A4 (de) Targeting von s. mutans-bindenden peptiden, konstrukte mit solchen peptiden und verwendungen davon
WO2014078268A8 (en) Anti-hemagglutinin antibodies and methods of use
WO2012162534A3 (en) Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
EP3215066A4 (de) Talarkuppel-befestigungsschaft
WO2014041115A3 (de) Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung
EP3232788A4 (de) Moleküle mit pestizidfunktion sowie zwischenprodukte, zusammensetzungen und verfahren im zusammenhang damit
EP3310373A4 (de) Thiol-en-basierte peptidheftung und verwendungen davon
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
WO2014091167A3 (fr) Composes cyclopropylboroniques, leur procede de preparation et leur utilisation
WO2012064743A3 (en) Methods for improving heart function
EP3322545A4 (de) Dampfstrahlsystem mit festem behälterdruck
EP3168475A4 (de) Befestigungsstruktur und elektrischer kompressor
EP2569327A4 (de) Eif4e-bindende peptide
WO2014170916A3 (en) Uricase mutants
EP3257868A4 (de) Peptide mit affinität für polydimethylsiloxan und verwendungen davon
EP3246360A4 (de) Transparente, hochtemperaturbeständige harzzusammensetzung

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13776426

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14426797

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015531567

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013776426

Country of ref document: EP